Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Mario Larocca"'
Autor:
Angela Damato, Francesca Bergamo, Lorenzo Antonuzzo, Guglielmo Nasti, Francesco Iachetta, Alessandra Romagnani, Erika Gervasi, Mario Larocca, Carmine Pinto
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
The NIVACOR trial is a phase II study assessing the efficacy and safety of nivolumab in combination with FOLFOXIRI/bevacizumab in first-line setting in patients affected by metastatic colorectal cancer (mCRC) RAS/BRAF mutated. We report safety run-in
Externí odkaz:
https://doaj.org/article/1889dd61354f4db5bf652ae999580102
Autor:
Angela Damato, Loredana De Marco, Silvia Serra, Mario Larocca, Alicia Garcia Arias, Ermanno Rondini, Carmine Pinto
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Pembrolizumab is a programmed death receptor-1 (PD-1) inhibitor that has been approved for treatment of a wide variety of malignancies including non-small-cell lung cancer (NSCLC). Immune-mediated colitis is a known adverse effect of pembrolizumab wh
Externí odkaz:
https://doaj.org/article/cca1e8cf47e74caa94ad4acc292904e7
Autor:
Lucia Mangone, Pamela Mancuso, Luigi Tarantini, Mario Larocca, Isabella Bisceglia, Angela Damato, Paolo Giorgi Rossi, Alessandro Navazio, Carmine Pinto
Publikováno v:
Cancers, Vol 13, Iss 23, p 5903 (2021)
The present research describes 25 years of cardiovascular mortality in a cohort of patients in Northern Italy. The study included patients with malignant cancer enrolled in the period of 1996–2019, and describes cardiovascular and cancer mortality
Externí odkaz:
https://doaj.org/article/92e6bfa2b3e942ae99808141b16e58e3
Autor:
Angela Damato, Mario Larocca, Ermanno Rondini, Massimo Menga, Carmine Pinto, Annibale Versari
Publikováno v:
Case Reports in Oncology, Vol 10, Iss 1, Pp 258-264 (2017)
Rhabdomyolysis is defined as dissolution of striped muscle characterized by leakage of intracellular muscle components into the circulation, which can ultimately lead to renal failure with a possible fatal outcome. This is an uncommon side effect of
Externí odkaz:
https://doaj.org/article/b440cfa7620945a6aee332abddcb6c5d
Autor:
Isabella Bisceglia, Mario Larocca, Alessandro Navazio, Angela Damato, Carmine Pinto, Lucia Mangone, Pamela Mancuso, Paolo Giorgi Rossi, Luigi Tarantini
Publikováno v:
Cancers
Cancers; Volume 13; Issue 23; Pages: 5903
Cancers, Vol 13, Iss 5903, p 5903 (2021)
Cancers; Volume 13; Issue 23; Pages: 5903
Cancers, Vol 13, Iss 5903, p 5903 (2021)
Simple Summary Research suggests that lengthening the prognosis in cancer patients (which is certainly a positive thing) requires greater attention to be paid to the onset of other pathologies. The increase in cardiovascular mortality in cancer patie
Autor:
Angela Damato, Francesca Bergamo, Lorenzo Antonuzzo, Guglielmo Nasti, Filippo Pietrantonio, Giuseppe Tonini, Evaristo Maiello, Roberto Bordonaro, Gerardo Rosati, Alessandra Romagnani, Francesco Iachetta, Mario Larocca, Giuseppe Maglietta, Nicola Normanno, Carmine Pinto
Publikováno v:
Journal of Clinical Oncology. 40:3509-3509
3509 Background: FOLFOXIRI plus bevacizumab (BEV) represents standard chemotherapy in first-line treatment of patients (pts) with metastatic colorectal cancer (mCRC). The NIVACOR study evaluates the addition of nivolumab (NIV) to FOLFOXIRI/BEV as fir
Autor:
Lorenzo Antonuzzo, Guglielmo Nasti, Angela Damato, Carmine Pinto, Francesca Bergamo, Annalisa Berselli, Alicia Garcia Arias, Francesco Iachetta, Mario Larocca, Alessandra Romagnani
Publikováno v:
Journal of Clinical Oncology. 39:37-37
37 Background: NIVACOR trial is an open-label, multicentric Italian phase II trial of FOLFOXIRI/bevacizumab in association with an anti-PD1 antibody, nivolumab, in patients (pts) with metastatic colorectal cancer (mCRC). We report preliminary safety
Autor:
Antonia Strippoli, Alessandra Cassano, Sabrina Rossi, Michele Basso, Giovanni Schinzari, Ettore D'Argento, Carlo Barone, Mario Larocca
Systemic inflammation has been proved to play a crucial role in promoting cancer progression and metastasis in many cancer types, including colorectal cancer (CRC). The aim of the present review was to provide an overview of studies regarding the pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b40cd8d766be1f1c7eba9108451316d5
http://hdl.handle.net/10807/171838
http://hdl.handle.net/10807/171838
Autor:
Ettore D'Argento, Maurizio Martini, Michele Basso, Alessandra Cassano, Carlo Barone, Sabrina Rossi, Michela Quirino, Mario Larocca, Riccardo Ricci, Giovanni Schinzari, Angelo Dipasquale, Antonia Strippoli, Maria Grazia Rodriquenz
Publikováno v:
Medicine
Several evidences showed that patients with gastrointestinal stromal tumors (GISTs) develop additional malignancies. However, thorough incidence of second tumors remains uncertain as the possibility of a common molecular pathogenesis. A retrospective
Molecular signature in malignant pleural mesothelioma (MPM): Preliminary data of Italian RAMES study
Autor:
R. Gnoni, Paolo Andrea Zucali, Giovanni Luca Ceresoli, Mario Larocca, Luca Boni, Maria Pagano, Carmine Pinto, Marcello Tiseo, Federica Torricelli, Candida Bonelli, Federico Cappuzzo, Federica Grosso, F. Zanelli, Alessia Ciarrocchi
Publikováno v:
Annals of Oncology. 29:viii674